Only 200,000 of 250 million obese on GLP-1, Says Novo Nordisk as semaglutide Patent expires
Novo Nordisk India chief says GLP-1 adoption remains low and the market untapped despite patent expiry opening it to generics
Novo Nordisk India chief says GLP-1 adoption remains low and the market untapped despite patent expiry opening it to generics
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
